In patients receiving treatments for metastatic cancer, elevated serum levels of bFGF and/or VEGF occurred more often in patients with progressive disease compared to patients that were responding to treatment (57% progressing patients versus 15% responding patients)41. This evidence concerns the gene VEGFA and metastatic malignant neoplasm.